Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

These viruses have only the capsid surrounding their genetic material. A virus budding from a host cell membrane. This sequence of steps forms the virus’s envelope. A host is an organism that a ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Many pathogenic viruses require a specific structure to be infectious, and their proteins form that structure in vivo with remarkable fidelity. The dynamical process by which protein conformations are ...

In a significant advancement, researchers from the Nanoscience Center (NSC) at the University of Jyväskylä, Finland, have unveiled innovative, ...

Bain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.

SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM ...